NCT03749993 (VISIONING) is a NA clinical trial of Screening in Prostate Cancer, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT03749993?

NCT03749993 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT03749993?

Interventions in NCT03749993: Screening.

What condition does NCT03749993 study?

NCT03749993 studies Prostate Cancer.

Is NCT03749993 still recruiting?

NCT03749993 is currently completed. Last updated 23 May 2023.

Last reviewed 2023-05-23 · How we verify

NCT03749993: VISIONING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a MRI-based Prostate Cancer Screening Program

Completed NA Last updated 23 May 2023

What this trial tests

NA trial testing Screening in Prostate Cancer in 241 participants. Completed in 1 May 2023.

Timeline

10 January 2019

Primary endpoint
1 April 2023

1 May 2023

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	241
Start date	10 January 2019
Primary completion	1 April 2023
Estimated completion	1 May 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Screening

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 46 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effort and resources (incl. costs) required to detect 20 clinically relevant prostate cancer (PCA) in a screening program based on bpMRI of the prostate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept.
Winkel DJ, Wetterauer C, Matthias MO, Lou B, et al · · 2020 · cited 36× · PMID 33202680 · DOI 10.3390/diagnostics10110951
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
Bratt O, Auvinen A, Arnsrud Godtman R, Hellström M, et al · · 2023 · cited 11× · PMID 39886507 · DOI 10.1136/bmjonc-2023-000039

Verify or expand the search:

Other trials of Screening

Trials testing the same drug.

NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
NCT07225374 — Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC · Phase 2 · recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
NCT06887569 — Using Financial Incentives and Screening to Increase Engagement With Mental Health Services Among College Students in Ch · NA · completed
NCT06439901 — Optimizing Bronchopulmonary Cancer Screening · NA · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03749993 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 23 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03749993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing